David G Standaert

David G Standaert

UNVERIFIED PROFILE

Are you David G Standaert?   Register this Author

Register author
David G Standaert

David G Standaert

Publications by authors named "David G Standaert"

Are you David G Standaert?   Register this Author

99Publications

1791Reads

18Profile Views

Child Neurology: Spastic paraparesis and dystonia with a novel mutation.

Neurology 2019 Sep;93(11):510-514

From the Departments of Neurology (M.D., D.G.S.) and Genetics (L.M., B.R.K.) and Division of Pediatric Neurology, Department of Pediatrics (S.R.), University of Alabama at Birmingham; and HudsonAlpha Institute for Biotechnology (G.M.C., M.D.A.), Huntsville, AL.

View Article

Download full-text PDF

Source
http://www.neurology.org/lookup/doi/10.1212/WNL.000000000000
Publisher Site
http://dx.doi.org/10.1212/WNL.0000000000008089DOI Listing
September 2019

Dystonia and levodopa-induced dyskinesias in Parkinson's disease: Is there a connection?

Neurobiol Dis 2019 Aug 22;132:104579. Epub 2019 Aug 22.

Department of Neurology, University of Alabama at Birmingham, Birmingham, AL 35294, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.nbd.2019.104579DOI Listing
August 2019

Reply to: DUOPA® is an Excellent Alternative Treatment but with Some Caveats.

Mov Disord Clin Pract 2019 Apr 27;6(4):336-337. Epub 2019 Mar 27.

University of Alabama at Birmingham Birmingham Alabama USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mdc3.12738DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6476597PMC
April 2019

Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases.

Neurology 2019 Feb;92(7):329-337

From the UC Gardner Neuroscience Institute and Gardner Family Center for Parkinson's Disease and Movement Disorders (A.J.E., J.A.V., L.M., A.M.), Department of Neurology, University of Cincinnati, OH; Edmond J. Safra Program in Parkinson's Disease and the Morton and Gloria Shulman Movement Disorders Clinic (A.E.L., A.F.), Toronto Western Hospital, University of Toronto; Krembil Research Institute (A.E.L., A.F.), Toronto, Canada; Parkinson's Disease and Movement Disorders Center (D.K.S.), Department of Neurology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; College of Medicine (K.A.J.), Mayo Clinic, Rochester, MN; Institute of Molecular and Clinical Sciences (F.M.), St George's University of London, UK; Division of Movement Disorders (R.S.), Department of Neurology and Department of Health Science Research, Mayo Clinic College of Medicine, Rochester, MN; Department of Neurology and the Pittsburgh Institute for Neurodegenerative Diseases (J.T.G., F.C.), University of Pittsburgh, PA; Department of Neurology (T.R.Y.), University of Kentucky, Lexington; Parkinson's Disease Research, Education and Clinical Center (C.M.T.), Neurology, San Francisco Veterans Affairs Medical Center; Department of Neurology (C.M.T.), University of California-San Francisco; Department of Neurology & Neurosurgery, Montreal Neurological Institute, and Department of Human Genetics (Z.G.-O.), McGill University, Canada; Parkinson & Other Movement Disorders Center UC San Diego (I.L.), Department of Neurosciences, Altman Clinical Translational Research Institute, La Jolla, CA; VA Puget Sound Health Care System and Department of Neurology (I.F.M., CP.Z.), University of Washington, Seattle; Department of Neurology (I.F.M.), University of Washington School of Medicine, Seattle; Center for Neurodegenerative Science (P.B.), Van Andel Research Institute, Grand Rapids, MI; Center for Neurological Restoration (H.H.F.) and Lou Ruvo Center for Brain Health, Neurological Institute (J.B.L.), Cleveland Clinic, OH; Department of Neurology (D.G.S.), University of Alabama at Birmingham; Consultorio y Laboratorio de Neurogenética (M.A.K.), Centro Universitario de Neurología "José María Ramos Mejía" y División Neurología, Hospital JM Ramos Mejía, Facultad de Medicina, UBA; Programa de Medicina de Precision y Genomica Clinica (M.A.K.), Instituto de Investigaciones en Medicina Traslacional, Facultad de Ciencias Biomédicas, Universidad Austral-CONICET, Buenos Aires, Argentina; Department of Neurology (M.A.S.), Massachusetts General Hospital, Boston; Division of Neuroscience (S.P.S.), Sanofi-Genzyme, Framingham, MA; Michael J. Fox Foundation for Parkinson's Research (T.S.), New York, NY; and College of Sciences (G.P.), University of Texas at San Antonio.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/WNL.0000000000006926DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6382364PMC
February 2019

Cannabidiol improves frequency and severity of seizures and reduces adverse events in an open-label add-on prospective study.

Epilepsy Behav 2018 10 9;87:131-136. Epub 2018 Aug 9.

Department of Neurology, University of Alabama at Birmingham, Birmingham, AL, USA; Division of Epilepsy, University of Alabama at Birmingham, Birmingham, AL, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.yebeh.2018.07.020DOI Listing
October 2018

Targeting of the class II transactivator attenuates inflammation and neurodegeneration in an alpha-synuclein model of Parkinson's disease.

J Neuroinflammation 2018 Aug 30;15(1):244. Epub 2018 Aug 30.

Center for Neurodegeneration and Experimental Therapeutics, Department of Neurology, The University of Alabama at Birmingham (UAB), 1719 6th Ave. South, CIRC 525, Birmingham, AL, 35294-0021, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12974-018-1286-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6117927PMC
August 2018

Anti-inflammatory drug use and progressive supranuclear palsy.

Parkinsonism Relat Disord 2018 03 6;48:89-92. Epub 2017 Dec 6.

Movement Disorder Center, Department of Neurosciences, University of California San Diego, San Diego, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.parkreldis.2017.11.346DOI Listing
March 2018

Peripheral monocyte entry is required for alpha-Synuclein induced inflammation and Neurodegeneration in a model of Parkinson disease.

Exp Neurol 2018 02 16;300:179-187. Epub 2017 Nov 16.

Center for Neurodegeneration and Experimental Therapeutics, Department of Neurology, The University of Alabama at Birmingham, Birmingham, AL 35294, USA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00144886173032
Publisher Site
http://dx.doi.org/10.1016/j.expneurol.2017.11.010DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5759972PMC
February 2018

The effect of unilateral subthalamic nucleus deep brain stimulation on depression in Parkinson's disease.

Brain Stimul 2017 May - Jun;10(3):651-656. Epub 2016 Dec 27.

Division of Movement Disorders, Department of Neurology, University of Alabama at Birmingham, Birmingham, AL, United States. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.brs.2016.12.014DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5410399PMC
December 2017

Genetic influences on cognition in progressive supranuclear palsy.

Mov Disord 2017 Dec 27;32(12):1764-1771. Epub 2017 Oct 27.

Department of Neurosciences, Parkinson and Movement Disorders Center, University of California, San Diego, California, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.27196DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5818145PMC
December 2017

What would Dr. James parkinson think today? Mutations in beta-glucocerebrosidase and risk of Parkinson's disease.

Mov Disord 2017 10;32(10):1341-1342

Department of Neurology, University of Alabama at Birmingham, Birmingham, Alabama, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.27206DOI Listing
October 2017

Strength of cholinergic tone dictates the polarity of dopamine D2 receptor modulation of striatal cholinergic interneuron excitability in DYT1 dystonia.

Exp Neurol 2017 09 3;295:162-175. Epub 2017 Jun 3.

Department of Cell, Developmental, and Integrative Biology, University of Alabama at Birmingham, Birmingham, AL 35294, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.expneurol.2017.06.005DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5561742PMC
September 2017

Dysregulation of BET proteins in levodopa-induced dyskinesia.

Neurobiol Dis 2017 06 9;102:125-132. Epub 2017 Mar 9.

Center for Neurodegeneration and Experimental Therapeutics, Department of Neurology, The University of Alabama at Birmingham, Birmingham, AL, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.nbd.2017.03.003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5410664PMC
June 2017

Evaluation of AZD1446 as a Therapeutic in DYT1 Dystonia.

Front Syst Neurosci 2017 13;11:43. Epub 2017 Jun 13.

Neurophysiology and Plasticity Laboratory, Fondazione Santa Lucia IRCCSRome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fnsys.2017.00043DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5468415PMC
June 2017

Biomarker-driven phenotyping in Parkinson's disease: A translational missing link in disease-modifying clinical trials.

Mov Disord 2017 03 24;32(3):319-324. Epub 2017 Feb 24.

Morton and Gloria Shulman Movement Disorders Center, Toronto Western Hospital and The Edmond J. Safra Program in PD, Toronto, Ontario, Canada, University of Toronto, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.26913DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5359057PMC
March 2017

Cholinergic regulation of striatal dopamine release: New light in dark basements.

Mov Disord 2016 12 7;31(12):1796. Epub 2016 Nov 7.

Center for Neurodegeneration and Experimental Therapeutics, Department of Neurology, The University of Alabama at Birmingham, Birmingham, Alabama, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.26846DOI Listing
December 2016

Glucocerebrosidase, Parkinson disease, and the "senses and intellect".

Ann Neurol 2016 11;80(5):660-661

Department of Neurology, University of Alabama at Birmingham, Birmingham, AL.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ana.24808DOI Listing
November 2016

How can rAAV-α-synuclein and the fibril α-synuclein models advance our understanding of Parkinson's disease?

J Neurochem 2016 10 4;139 Suppl 1:131-155. Epub 2016 May 4.

From the Center for Neurodegeneration and Experimental Therapeutics, Department of Neurology, The University of Alabama at Birmingham, Birmingham, Alabama.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jnc.13627DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5040622PMC
October 2016

Ser(P)-1292 LRRK2 in urinary exosomes is elevated in idiopathic Parkinson's disease.

Mov Disord 2016 10;31(10):1543-1550

Center for Neurodegeneration and Experimental Therapeutics, Department of Neurology, University of Alabama at Birmingham, Birmingham, Alabama, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5053851PMC
http://dx.doi.org/10.1002/mds.26686DOI Listing
October 2016

SNPing SCNA regulatory elements gives a CRISPR view of genetic susceptibility in Parkinson's disease.

Mov Disord 2016 10;31(10):1479

Center for Neurodegeneration and Experimental Therapeutics, Department of Neurology, The University of Alabama at Birmingham, Birmingham, Alabama, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.26747DOI Listing
October 2016

CoQ10 in progressive supranuclear palsy: A randomized, placebo-controlled, double-blind trial.

Neurol Neuroimmunol Neuroinflamm 2016 Oct 2;3(5):e266. Epub 2016 Aug 2.

Department of Neurology (D.A., S.A.S.), Lahey Hospital & Medical Center, Burlington, MA; Department of Neurology and Neurobiology (D.G.S., T.A.Y.), University of Alabama Hospital, Birmingham; Department of Neurology (R.W.H.), University of Vermont College of Medicine, Burlington; Department of Neurology (D.K.S.), Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; and Research Design Center/Biostatistics Research Center (S.P., R.R.), Tufts Clinical & Translational Science Institute, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/NXI.0000000000000266DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4990260PMC
October 2016

Fractalkine Signaling Regulates the Inflammatory Response in an α-Synuclein Model of Parkinson Disease.

PLoS One 2015 15;10(10):e0140566. Epub 2015 Oct 15.

Center for Neurodegeneration and Experimental Therapeutics, Department of Neurology, The University of Alabama at Birmingham, Birmingham, Alabama, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0140566PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4607155PMC
June 2016

The Metabotropic Glutamate Receptor 4 Positive Allosteric Modulator ADX88178 Inhibits Inflammatory Responses in Primary Microglia.

J Neuroimmune Pharmacol 2016 06 12;11(2):231-7. Epub 2016 Feb 12.

Center for Neurodegeneration and Experimental Therapeutics, Department of Neurology, The University of Alabama at Birmingham, Birmingham, AL, 35294, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11481-016-9655-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4848139PMC
June 2016

Biomarkers in Parkinson's disease: From pathophysiology to early diagnosis.

Mov Disord 2016 06;31(6):769-70

Clinica Neurologica, Università degli Studi di Perugia, Ospedale S. Maria della Misericordia, Perugia, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.26683DOI Listing
June 2016

Dynamic DNA Methylation Regulates Levodopa-Induced Dyskinesia.

J Neurosci 2016 06;36(24):6514-24

Center for Neurodegeneration and Experimental Therapeutics, Department of Neurology, University of Alabama at Birmingham, Birmingham, Alabama 35294

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1523/JNEUROSCI.0683-16.2016DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5015786PMC
June 2016

Effects of subthalamic nucleus deep brain stimulation on objective sleep outcomes in Parkinson's disease.

Mov Disord Clin Pract 2017 Mar-Apr;4(2):183-190. Epub 2016 Jun 6.

1Division of Movement Disorders, Department of Neurology, University of Alabama at Birmingham, Birmingham, AL.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mdc3.12375DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5600204PMC
June 2016

microRNA-155 Regulates Alpha-Synuclein-Induced Inflammatory Responses in Models of Parkinson Disease.

J Neurosci 2016 Feb;36(8):2383-90

Center for Neurodegeneration and Experimental Therapeutics, Department of Neurology, The University of Alabama at Birmingham, Birmingham, Alabama 35294

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1523/JNEUROSCI.3900-15.2016DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4764660PMC
February 2016

Invisible Killers.

Mov Disord 2016 Jan 9;31(1):44. Epub 2016 Jan 9.

Center for Neurodegeneration and Experimental Therapeutics, Department of Neurology, The University of Alabama at Birmingham, Birmingham, Alabama, USA.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/mds.26465
Publisher Site
http://dx.doi.org/10.1002/mds.26465DOI Listing
January 2016

Role of α-synuclein in inducing innate and adaptive immunity in Parkinson disease.

J Parkinsons Dis 2015 ;5(1):1-19

Center for Neurodegeneration and Experimental Therapeutics, Department of Neurology, University of Alabama at Birmingham, Alabama, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/JPD-140491DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4405142PMC
November 2015

Fractalkine Signaling Regulates the Inflammatory Response in an α-Synuclein Model of Parkinson Disease.

PLoS One 2015 15;10(10):e0140566. Epub 2015 Oct 15.

Center for Neurodegeneration and Experimental Therapeutics, Department of Neurology, The University of Alabama at Birmingham, Birmingham, Alabama, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0140566PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4607155PMC
June 2016

Scientific perspectives.

Mov Disord 2014 Sep;29(10):1230

Associate Editor, Scientific Perspectives.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.26015DOI Listing
September 2014

Differential LRRK2 expression in the cortex, striatum, and substantia nigra in transgenic and nontransgenic rodents.

J Comp Neurol 2014 Aug 12;522(11):2465-80. Epub 2014 Apr 12.

Center for Neurodegeneration and Experimental Therapeutics, Department of Neurology, University of Alabama at Birmingham, Birmingham, Alabama, 35294.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cne.23583DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4076169PMC
August 2014

Fiber-modified adenovirus for central nervous system Parkinson's disease gene therapy.

Viruses 2014 Aug 21;6(8):3293-310. Epub 2014 Aug 21.

Department of Radiation Oncology, School of Medicine, Washington University in St. Louis, St. Louis, MO 63108, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/v6083293DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4147696PMC
August 2014

Reaping what you sow: Cross-seeding between aggregation-prone proteins in neurodegeneration.

Mov Disord 2014 Mar 2;29(3):306. Epub 2014 Jan 2.

Center for Neurodegeneration and Experimental Therapeutics, Department of Neurology, University of Alabama at Birmingham, Birmingham, Alabama, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.25766DOI Listing
March 2014

Rotigotine polyoxazoline conjugate SER-214 provides robust and sustained antiparkinsonian benefit.

Mov Disord 2013 Oct 3;28(12):1675-82. Epub 2013 Sep 3.

Center for Neurodegeneration and Experimental Therapeutics, Department of Neurology, University of Alabama-Birmingham, Birmingham, Alabama, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.25625DOI Listing
October 2013

Metabolomics and the search for biomarkers in Parkinson's disease.

Mov Disord 2013 Oct 18;28(12):1620-1. Epub 2013 Sep 18.

Department of Neurology, University of Alabama at Birmingham, Birmingham, Alabama, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.25644DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4050667PMC
October 2013

Evaluation of TorsinA as a target for Parkinson disease therapy in mouse models.

PLoS One 2012 21;7(11):e50063. Epub 2012 Nov 21.

Center for Neurodegeneration and Experimental Therapeutics, Department of Neurology, The University of Alabama at Birmingham, Birmingham, Alabama, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0050063PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3503809PMC
May 2013

CD4+ regulatory and effector/memory T cell subsets profile motor dysfunction in Parkinson's disease.

J Neuroimmune Pharmacol 2012 Dec 11;7(4):927-38. Epub 2012 Oct 11.

Department of Pharmacology and Experimental Neuroscience, Center for Neurodegenerative Disorders, University of Nebraska Medical Center, Omaha, NE 68198-5880, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11481-012-9402-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3515774PMC
December 2012

The gamma chain subunit of Fc receptors is required for alpha-synuclein-induced pro-inflammatory signaling in microglia.

J Neuroinflammation 2012 Nov 27;9:259. Epub 2012 Nov 27.

Center for Neurodegeneration and Experimental Therapeutics, Department of Neurology, The University of Alabama at Birmingham, 1719 6th Ave. South, CIRC 516, Birmingham, AL 35294-0021, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1742-2094-9-259DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3526448PMC
November 2012

Cholinergic dysregulation produced by selective inactivation of the dystonia-associated protein torsinA.

Neurobiol Dis 2012 Sep 3;47(3):416-27. Epub 2012 May 3.

Clinica Neurologica, Dipartimento di Neuroscienze, Università di Roma Tor Vergata and Fondazione Santa Lucia, I.R.C.C.S., Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.nbd.2012.04.015DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3392411PMC
September 2012

Alteration of striatal dopaminergic neurotransmission in a mouse model of DYT11 myoclonus-dystonia.

PLoS One 2012 16;7(3):e33669. Epub 2012 Mar 16.

Department of Neurology, School of Medicine, University of Florida, Gainesville, Florida, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0033669PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3306281PMC
August 2012

Cholinergic dysfunction alters synaptic integration between thalamostriatal and corticostriatal inputs in DYT1 dystonia.

J Neurosci 2012 Aug;32(35):11991-2004

Department of Neuroscience, University Tor Vergata/Laboratory of Neurophysiology and Synaptic Plasticity, Fondazione Santa Lucia Istituto di Ricovero e Cura a Carattere Scientifico, 00143 Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1523/JNEUROSCI.0041-12.2012DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3471539PMC
August 2012

Motor deficits and decreased striatal dopamine receptor 2 binding activity in the striatum-specific Dyt1 conditional knockout mice.

PLoS One 2011 12;6(9):e24539. Epub 2011 Sep 12.

Department of Neurology, College of Medicine, University of Florida, Gainesville, Florida, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0024539PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3171455PMC
June 2012

LRRK2 inhibition attenuates microglial inflammatory responses.

J Neurosci 2012 Feb;32(5):1602-11

Department of Neurology, University of Alabama at Birmingham, Birmingham, Alabama 35294, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1523/JNEUROSCI.5601-11.2012DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3532034PMC
February 2012

Unilateral subthalamic nucleus deep brain stimulation improves sleep quality in Parkinson's disease.

Parkinsonism Relat Disord 2012 Jan 15;18(1):63-8. Epub 2011 Sep 15.

Division of Movement Disorders, Department of Neurology, University of Alabama at Birmingham, Birmingham, AL, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.parkreldis.2011.09.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249526PMC
January 2012

Update on the pathology of dystonia.

Neurobiol Dis 2011 May 8;42(2):148-51. Epub 2011 Jan 8.

Center for Neurodegeneration and Experimental Therapeutics, University of Alabama at Birmingham, AL 35294, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.nbd.2011.01.012DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3073692PMC
May 2011

Altered dendritic morphology of Purkinje cells in Dyt1 ΔGAG knock-in and purkinje cell-specific Dyt1 conditional knockout mice.

PLoS One 2011 Mar 29;6(3):e18357. Epub 2011 Mar 29.

Center for Neurodegeneration and Experimental Therapeutics, Department of Neurology, School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0018357PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3066238PMC
March 2011

A neuroprotective role for angiogenin in models of Parkinson's disease.

J Neurochem 2011 Feb 22;116(3):334-41. Epub 2010 Dec 22.

Department of Neurobiology, University of Alabama at Birmingham, Birmingham, AL 35294, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1471-4159.2010.07112.xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3048053PMC
February 2011

Fcγ receptors are required for NF-κB signaling, microglial activation and dopaminergic neurodegeneration in an AAV-synuclein mouse model of Parkinson's disease.

Mol Neurodegener 2010 Oct 26;5:42. Epub 2010 Oct 26.

Center for Neurodegeneration and Experimental Therapeutics, Department of Neurology, The University of Alabama at Birmingham, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1750-1326-5-42DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2975641PMC
October 2010

Target validation: the Parkinson disease perspective.

Dis Model Mech 2010 May-Jun;3(5-6):259-62

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1242/dmm.004192DOI Listing
September 2010

VPS41, a protein involved in lysosomal trafficking, is protective in Caenorhabditis elegans and mammalian cellular models of Parkinson's disease.

Neurobiol Dis 2010 Feb 20;37(2):330-8. Epub 2009 Oct 20.

Center for Neurodegeneration and Experiment Therapeutics, University of Alabama at Birmingham, CIRC 516, Birmingham, AL 35294, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.nbd.2009.10.011DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2818321PMC
February 2010

Targets for neuroprotection in Parkinson's disease.

Biochim Biophys Acta 2009 Jul 1;1792(7):676-87. Epub 2008 Oct 1.

Department of Neurology, Center for Neurodegeneration and Experimental Therapeutics, University of Alabama at Birmingham, Birmingham, AL 35294, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbadis.2008.09.009DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2740981PMC
July 2009

Dysregulation of CalDAG-GEFI and CalDAG-GEFII predicts the severity of motor side-effects induced by anti-parkinsonian therapy.

Proc Natl Acad Sci U S A 2009 Feb 26;106(8):2892-6. Epub 2009 Jan 26.

Department of Brain and Cognitive Sciences and the McGovern Institute for Brain Research, Massachusetts Institute of Technology, 43 Vassar Street, Cambridge, MA 02139, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.0812822106DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2650361PMC
February 2009

Targeted overexpression of human alpha-synuclein triggers microglial activation and an adaptive immune response in a mouse model of Parkinson disease.

J Neuropathol Exp Neurol 2008 Dec;67(12):1149-58

Center for Neurodegeneration and Experimental Therapeutics, The University of Alabama at Birmingham, Alabama 35294-0021, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/NEN.0b013e31818e5e99DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2753200PMC
December 2008

Striatal histone modifications in models of levodopa-induced dyskinesia.

J Neurochem 2008 Jul 1;106(1):486-94. Epub 2008 Jul 1.

Center for Neurodegeneration and Experimental Therapeutics, Department of Neurology, University of Alabama at Birmingham, AL 35294-0017, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1471-4159.2008.05417.xDOI Listing
July 2008

Transcriptional dysregulation in a transgenic model of Parkinson disease.

Neurobiol Dis 2008 Mar 28;29(3):515-28. Epub 2007 Nov 28.

Neurology Department, Center for Neurodegeneration and Experimental Therapeutics, University of Alabama at Birmingham, Birmingham, AL 35294, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.nbd.2007.11.008DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2707844PMC
March 2008

The pathophysiological basis of dystonias.

Nat Rev Neurosci 2008 Mar;9(3):222-34

Department of Neurology and Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrn2337DOI Listing
March 2008

Design of clinical trials of gene therapy in Parkinson disease.

Exp Neurol 2008 Jan 31;209(1):41-7. Epub 2007 Aug 31.

Center for Neurodegeneration and Experimental Therapeutics, University of Alabama at Birmingham, Birmingham, AL 35294, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.expneurol.2007.08.012DOI Listing
January 2008

Biochemical fractionation of brain tissue for studies of receptor distribution and trafficking.

Curr Protoc Neurosci 2008 Jan;Chapter 1:Unit 1.16

MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/0471142301.ns0116s42DOI Listing
January 2008

Angiotensin II protects against alpha-synuclein toxicity and reduces protein aggregation in vitro.

Biochem Biophys Res Commun 2007 Nov 21;363(3):846-51. Epub 2007 Sep 21.

MassGeneral Institute for Neurodegenerative Disease, Harvard Medical School, Massachusetts General Hospital, Charlestown, MA 02129, USA.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S0006291X0702034
Publisher Site
http://dx.doi.org/10.1016/j.bbrc.2007.09.043DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2707356PMC
November 2007

Dopamine release is impaired in a mouse model of DYT1 dystonia.

J Neurochem 2007 Aug 30;102(3):783-8. Epub 2007 Apr 30.

MassGeneral Institute for Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1471-4159.2007.04590.xDOI Listing
August 2007

Data mining techniques to detect motor fluctuations in Parkinson's disease.

Conf Proc IEEE Eng Med Biol Soc 2004 ;7:4766-9

Department of Physical Medicine & Rehabilitation, Spaulding Rehabilitation Hospital, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1109/IEMBS.2004.1404319DOI Listing
June 2007

Effects of gender on nigral gene expression and parkinson disease.

Neurobiol Dis 2007 Jun 3;26(3):606-14. Epub 2007 Mar 3.

Neurology Department, Massachusetts General Hospital, 114 16th Street, CNY114-2250, Charlestown, MA 02129, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.nbd.2007.02.009DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2435483PMC
June 2007

Pharmacological inhibition of PARP-1 reduces alpha-synuclein- and MPP+-induced cytotoxicity in Parkinson's disease in vitro models.

Biochem Biophys Res Commun 2007 Jun 5;357(3):596-602. Epub 2007 Apr 5.

Department of Neurology, Harvard Medical School and MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Bldg. 114-3300, 16th St., Charlestown, MA 02129-4404, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbrc.2007.03.163DOI Listing
June 2007

Dopaminergic neuron loss and up-regulation of chaperone protein mRNA induced by targeted over-expression of alpha-synuclein in mouse substantia nigra.

J Neurochem 2007 Mar 4;100(6):1449-57. Epub 2007 Jan 4.

Alzheimer's Disease Research Unit, MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Charlestown, Massachusetts 02129, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1471-4159.2006.04310.xDOI Listing
March 2007

Molecular markers of early Parkinson's disease based on gene expression in blood.

Proc Natl Acad Sci U S A 2007 Jan 10;104(3):955-60. Epub 2007 Jan 10.

Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, 65 Landsdowne Street, Cambridge, MA 02139, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.0610204104DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1766335PMC
January 2007

Dopamine D1 activation potentiates striatal NMDA receptors by tyrosine phosphorylation-dependent subunit trafficking.

J Neurosci 2006 Apr;26(17):4690-700

MassGeneral Institute for Neurodegenerative Disease, Harvard Medical School, Massachusetts General Hospital, Charlestown, Massachusetts 02129, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1523/JNEUROSCI.0792-06.2006DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6674081PMC
April 2006

Somatic mitochondrial DNA mutations in single neurons and glia.

Neurobiol Aging 2005 Nov-Dec;26(10):1343-55. Epub 2004 Dec 29.

Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02129, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.neurobiolaging.2004.11.008DOI Listing
January 2006

Alpha-synuclein and chaperones in dementia with Lewy bodies.

J Neuropathol Exp Neurol 2005 Dec;64(12):1058-66

Massachusetts General Institute for Neurodegenerative Disease, Massachusetts General Hospital, Charlestown, Massachusetts 02129, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/01.jnen.0000190063.90440.69DOI Listing
December 2005